ReCode Therapeutics

Better delivery platforms can unleash the true potential of genetic medicines. These must deliver drugs beyond the liver – to the lungs, spleen, and beyond. Learn how we are powering the next wave of genetic medicines through superior delivery: recodetx.com

We’re at the @mRNAConference this week. Come join our session at 3:10pm ET where David Lockhart, our President and CSO, will be talking about our SORT LNP-formulated mRNA for the treatment of #PrimaryCiliaryDyskinesia.

On this week’s episode of The Long Run podcast, our CEO @SulimanShehnaaz had the opportunity to speak with @ldtimmerman about her #leadership journey, our strategy and vision, and how we're improving the delivery of #geneticmedicine. Take a listen! bit.ly/3NLHmtj

We want to say thank you to everyone who participated in the #NACFC2022 conference this year. We’re truly inspired by the passionate people we met who are carrying forward research to treat the thousands of people living with #CysticFibrosis.

This month, we’ll be participating in the @CreditSuisse and @Stifel Healthcare Conferences. We’re looking forward to sharing more about our novel #genetic #medicines delivery platform and pipeline of disease-modifying #mRNA & gene correction therapeutics. recodetx.com/recode-therape…

We’re excited to attend #NACFC2022 this year with other members of the #CysticFibrosis community. Please visit us at booth #1020 to learn more about our investigational therapy for CF patients who have nonsense mutations & do not respond to currently approved CFTR modulators.

We’re very proud to have been nominated for the 2022 #PrixGalien award for “Best Startup in the Pharmaceutical or Biotechnology Industry.” Thank you @GalienFdn for this honor and congratulations to all of this year’s winners and nominees for your work to improve human health!

This #LungHealthDay, we recognize the importance of #LungHealth and show support to those living with a rare lung condition. At Recode, we aim to improve the lives of these patients by developing genetic medicines with superior delivery. Learn more at recodetx.com/pipeline/

Will we see you at #PODD2022 in Boston next week? On Monday, our director of BD Ariel Kantor will talk about how our novel SORT LNP platform is overcoming the limitations of conventional LNPs to enable superior delivery of #RNA and next-gen gene correction therapeutics

Learn more about our platform and genetic medicine which is currently in development in Cystic Fibrosis News Today: cysticfibrosisnewstoday.com/news/aerosoliz….

Moreover, our SORT LNP platform can deliver optimized, functional CFTR mRNA as an aerosol to the intended secretory and basal cells.

Did you know October is #HealthyLungMonth? We wanted to take this opportunity to shed some light on the research we are undertaking to improve the lives of patients with #CysticFibrosis, a rare condition that affects the lungs.

#PrimaryCiliaryDyskinesia, or #PCD, is challenging to diagnose leading to both missed diagnosis and misdiagnosis. Although there is no treatment for PCD, an early diagnosis can help protect and delay damage to the lungs. Source: nhlbi.nih.gov/health/primary…. #PCDAwarenessMonth

#CysticFibrosis (CF) can make it very difficult to breathe. This #HealthyLungMonth, we’re raising awareness about this disease and the way in which it affects the lungs. Learn more about CF and our approach to a CFTR mRNA therapy at recodetx.com/pipeline/.

Currently, there is no cure for this disease. Most patients take medicines only to manage the condition. At #ReCodeTx, we’re working to develop life-saving therapeutics for patients with PCD. Learn more about our work here: recodetx.com/pipeline/

Primary ciliary dyskinesia, or PCD, is a rare genetic condition caused by mutations in hair-like structures called cilia found on many cells including in the lungs. The cilia of PCD patients do not work properly which increases the risk of lung infection.

October is #PCDAwarenessMonth. Have you heard of PCD? - I know someone who has it. - No. What is it?

This week at EMBO #Cilia2022 in Cologne, our own Mirko Hennig, presented important preclinical data that showed our investigational inhaled DNAI1 mRNA treatment for #PCD has low immune reactivity, rescues ciliary function & results in long-lasting functional recovery.